The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

2018 Korean Heart Rhythm Society Guidelines for The Rate Control of Atrial Fibrillation

2018 대한부정맥학회 심방세동 환자의 심박수 조절 지침

  • Lim, Woo-Hyun (Division of Cardiology, Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine) ;
  • Choi, Eue-Keun (Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Joung, Boyoung (Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine) ;
  • Choi, Kee-Joon (Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 임우현 (서울대학교 보라매병원 순환기내과) ;
  • 최의근 (서울대학교 서울대학교병원 순환기내과) ;
  • 정보영 (연세대학교 세브란스병원 심장내과) ;
  • 최기준 (울산대학교 서울아산병원 심장내과)
  • Published : 2018.04.01
⟨ Previous Next ⟩

Abstract

Atrial fibrillation (AF) is characterized by irregular and relatively rapid heart rate, which occasionally causes symptoms such as palpitations, dyspnea, or reduced exercise capacity. Controlling the ventricular rate is a mainstay for the symptom management of patients with AF. Rate control can be achieved with beta-blockers, non-dihydropyridine calcium channel blockers, digoxin, or combination therapy. Rhythm control is an option for patients in whom appropriate rate control cannot be achieved or who have persistent symptoms despite rate control. The choices of drug and target heart rate are usually specified by international guidelines for AF management. However, pivotal trials included in those guidelines enrolled only a small number of Asian subjects, which limit application of those guidelines to a Korean population. The Korean Heart Rhythm Society organized the Korean AF Management Guideline Committee and analyzed all available studies regarding management of AF including studies with Korean patients. Then, expert consensus or guidelines for optimal management in Korean patients with AF were achieved after systematic review with intensive discussion. This article provides general principles for rate control therapy in Korean patients with AF.

Keywords

References

  1. Nikolaidou T, Channer KS. Chronic atrial fibrillation: a systematic review of medical heart rate control management. Postgrad Med J 2009;85:303-312. https://doi.org/10.1136/pgmj.2008.068908
  2. Heist EK, Mansour M, Ruskin JN. Rate control in atrial fibrillation: targets, methods, resynchronization considerations. Circulation 2011;124:2746-2755. https://doi.org/10.1161/CIRCULATIONAHA.111.019919
  3. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med 1997;29:135-140. https://doi.org/10.1016/S0196-0644(97)70319-6
  4. Siu CW, Lau CP, Lee WL, Lam KF, Tse HF. Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation. Crit Care Med 2009;37:2174-2179; quiz 2180. https://doi.org/10.1097/CCM.0b013e3181a02f56
  5. Tisdale JE, Padhi ID, Goldberg AD, et al. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery. Am Heart J 1998;135(5 Pt 1):739-747. https://doi.org/10.1016/S0002-8703(98)70031-6
  6. Scheuermeyer FX, Grafstein E, Stenstrom R, et al. Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness. Acad Emerg Med 2013;20:222-230. https://doi.org/10.1111/acem.12091
  7. Platia EV, Michelson EL, Porterfield JK, Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989;63:925-929. https://doi.org/10.1016/0002-9149(89)90141-0
  8. Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. J Am Coll Cardiol 1991;18:891-897. https://doi.org/10.1016/0735-1097(91)90743-S
  9. Steinberg JS, Katz RJ, Bren GB, Buff LA, Varghese PJ. Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise. J Am Coll Cardiol 1987;9:405-411. https://doi.org/10.1016/S0735-1097(87)80396-0
  10. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83:52-60. https://doi.org/10.1161/01.CIR.83.1.52
  11. Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998;81:594-598. https://doi.org/10.1016/S0002-9149(97)00962-4
  12. Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 2001;29:1149-1153. https://doi.org/10.1097/00003246-200106000-00011
  13. Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J 1995;16:521-528. https://doi.org/10.1093/oxfordjournals.eurheartj.a060945
  14. Kotecha D, Holmes J, Krum H, et al. Efficacy of ${\beta}$ blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:2235-2243. https://doi.org/10.1016/S0140-6736(14)61373-8
  15. Yu HT, Yang PS, Lee H, et al. Outcomes of rate-control treatment in patients with atrial fibrillation and heart failure-a nationwide cohort study. Circ J 2018;82:652-658. https://doi.org/10.1253/circj.CJ-17-0669
  16. Kotecha D, Manzano L, Krum H, et al. Effect of age and sex on efficacy and tolerability of ${\beta}$ blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ 2016;353:i1855.
  17. Ulimoen SR, Enger S, Carlson J, et al. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol 2013;111:225-230. https://doi.org/10.1016/j.amjcard.2012.09.020
  18. Kim MS, Lee JH, Kim EJ, et al. Korean guidelines for diagnosis and management of chronic heart failure. Korean Circ J 2017;47:555-643. https://doi.org/10.4070/kcj.2017.0009
  19. Elkayam U, Shotan A, Mehra A, Ostrzega E. Calcium channel blockers in heart failure. J Am Coll Cardiol 1993;22(4 Suppl A):139A-144A. https://doi.org/10.1016/0735-1097(93)90478-J
  20. Ulimoen SR, Enger S, Pripp AH, et al. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J 2014;35:517-524. https://doi.org/10.1093/eurheartj/eht429
  21. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533. https://doi.org/10.1056/NEJM199702203360801
  22. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006;114:397-403. https://doi.org/10.1161/CIRCULATIONAHA.106.628347
  23. Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol 2014;64:660-668. https://doi.org/10.1016/j.jacc.2014.03.060
  24. Hallberg P, Lindbäck J, Lindahl B, Stenestrand U, Melhus H; RIKS-HIA group. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol 2007;63:959-971. https://doi.org/10.1007/s00228-007-0346-9
  25. Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J 2013;34:1481-1488. https://doi.org/10.1093/eurheartj/ehs348
  26. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J 2013;34:1489-1497. https://doi.org/10.1093/eurheartj/eht120
  27. Flory JH, Ky B, Haynes K, et al. Observational cohort study of the safety of digoxin use in women with heart failure. BMJ Open 2012;2:e000888. https://doi.org/10.1136/bmjopen-2012-000888
  28. Allen LA, Fonarow GC, Simon DN, et al. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol 2015;65:2691-2698. https://doi.org/10.1016/j.jacc.2015.04.045
  29. Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015;351:h4451.
  30. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003;42:1944-1951. https://doi.org/10.1016/j.jacc.2003.07.020
  31. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol 1999;33:304-310. https://doi.org/10.1016/S0735-1097(98)00561-0
  32. Koh KK, Kwon KS, Park HB, et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol 1995;75:88-90. https://doi.org/10.1016/S0002-9149(99)80538-4
  33. Tsuneda T, Yamashita T, Fukunami M, et al. Rate control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial Fibrillation (QOLAF) Study. Circ J 2006;70:965-970. https://doi.org/10.1253/circj.70.965
  34. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010;362:1363-1373. https://doi.org/10.1056/NEJMoa1001337
  35. Groenveld HF, Crijns HJ, Van den Berg MP, et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol 2011;58:1795-1803. https://doi.org/10.1016/j.jacc.2011.06.055
  36. Van Gelder IC, Wyse DG, Chandler ML, et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006;8:935-942. https://doi.org/10.1093/europace/eul106
  37. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004;43:1201-1208. https://doi.org/10.1016/j.jacc.2003.11.032
  38. Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6-14. https://doi.org/10.1093/europace/eut263
  39. Li SJ, Sartipy U, Lund LH, et al. Prognostic significance of resting heart rate and use of beta-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish Heart Failure Registry. Circ Heart Fail 2015;8:871-879. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002285
  40. Queiroga A, Marshall HJ, Clune M, Gammage MD. Ablate and pace revisited: long term survival and predictors of permanent atrial fibrillation. Heart 2003;89:1035-1038. https://doi.org/10.1136/heart.89.9.1035
  41. Lim KT, Davis MJ, Powell A, et al. Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial. Europace 2007;9:498-505. https://doi.org/10.1093/europace/eum091
  42. Geelen P, Brugada J, Andries E, Brugada P. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol 1997;20(2 Pt 1):343-348. https://doi.org/10.1111/j.1540-8159.1997.tb06179.x
  43. Wang RX, Lee HC, Hodge DO, et al. Effect of pacing method on risk of sudden death after atrioventricular node ablation and pacemaker implantation in patients with atrial fibrillation. Heart Rhythm 2013;10:696-701. https://doi.org/10.1016/j.hrthm.2013.01.021
  44. Chatterjee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, Choudhry NK, Singh JP. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. Circ Arrhythm Electrophysiol 2012;5:68-76. https://doi.org/10.1161/CIRCEP.111.967810
  45. Bradley DJ, Shen WK. Overview of management of atrial fibrillation in symptomatic elderly patients: pharmacologic therapy versus AV node ablation. Clin Pharmacol Ther 2007;81:284-287. https://doi.org/10.1038/sj.clpt.6100062
  46. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation : a meta-analysis. Circulation 2000;101:1138-1144. https://doi.org/10.1161/01.CIR.101.10.1138
  47. Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001;344:1043-1051. https://doi.org/10.1056/NEJM200104053441403
  48. Hess PL, Jackson KP, Hasselblad V, Al-Khatib SM. Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and metaanalysis. Curr Cardiol Rep 2013;15:330. https://doi.org/10.1007/s11886-012-0330-6
  49. Hoppe UC, Casares JM, Eiskjaer H, et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 2006;114:18-25. https://doi.org/10.1161/CIRCULATIONAHA.106.614560
  50. Chatterjee NA, Upadhyay GA, Ellenbogen KA, Hayes DL, Singh JP. Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular pacing mode. Eur J Heart Fail 2012;14:661-667. https://doi.org/10.1093/eurjhf/hfs036

Cited by

  1. Guideline of atrial fibrillation management vol.62, pp.5, 2019, https://doi.org/10.5124/jkma.2019.62.5.265